spbmedicalrecordsНовые Санкт-Петербургские врачебные ведомостиNew St. Petersburg Medical Records1609-2201Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова10.24884/1609-2201-2024-103-3-75-80spbmedicalrecords-37Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSТромбоэмболические осложнения при воспалительных заболеваниях кишечникаThromboembolic complications in inflammatory bowel diseasehttps://orcid.org/0000-0002-2133-4849БарышеваО. Ю.BaryshevaO. Yu.

Барышева Ольга Юрьевна, доктор медицинских наук, профессор, профессор кафедры госпитальной терапии Медицинского института им. А. П. Зильбера, Петрозаводский государственный университет; заведующая нефрологическим отделением, Республиканская больница им. В. А. Баранова

185910,  Республика  Карелия, г. Петрозаводск, пр. Ленина, 33

Olga Yu. Barysheva, Dr. of Sci. (Med.), Professor, Professor of the Department of Hospital Therapy from Medical Institute named after A. P. Zilber, Petrozavodsk State University; Head of Nephrology Department Republic hospital named after V. A. Baranov

Lenin Str., 33, 185910, Petrozavodsk, Republic of Karelia

hosptherapy@mail.ruhttps://orcid.org/0009-0006-8073-9703ГолубеваА. М.GolubevaA. M.

Голубева Анна Михайловна, гастроэнтеролог нефрологического отделения

г. Петрозаводск

Anna M. Golubeva, Gastroenterologist of Nephrology Department 

Petrozavodsk

harloev@mail.ruПетрозаводский государственный университет; Республиканская больница имени В. А. БарановаРоссияPetrozavodsk State University; Republic hospital named after V. A. BaranovRussian FederationРеспубликанская больница имени В. А. БарановаРоссияRepublic hospital named after V. A. BaranovRussian Federation202428012025037580Copyright © Барышева О.Ю., Голубева А.М., 20252025Барышева О.Ю., Голубева А.М.Barysheva O.Y., Golubeva A.M.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.docved.ru/jour/article/view/37

В настоящее время отмечается рост заболеваемости и распространенности воспалительных заболеваний кишечника. Особенностью данной группы заболеваний, помимо поражения желудочно-кишечного тракта, является высокая частота внекишечных проявлений, среди которых особый интерес вызывают тромботические осложнения, угрожающие жизни, мультифакторные, с малоизученным патогенезом, влияющие на проводимую терапию. Перед практикующим врачом стоит вопрос назначения антитромбоцитарной или антикоагулянтной терапии конкретному пациенту как с высоким риском кишечного кровотечения, так и с высоким риском тромбозов и тромбоэмболических осложнений. В статье представлены литературные данные и собственные наблюдения по данной теме. Приведены современные рекомендации по ведению пациентов. Представлен клинический случай, демонстрирующий особенности ведения пациента с болезнью Крона и тромботическими осложнениями.

Currently, there is an increase in the incidence and prevalence of inflammatory bowel diseases. A feature of this group of diseases, in addition to damage to the gastrointestinal tract, is the high frequency of extra-intestinal manifestations, among which thrombotic complications, life-threatening, multifactorial, with little studied pathogenesis, affecting  the therapy, are of particular interest. The practitioner is faced with the  issue  of  prescribing  antiplatelet  or  anticoagulant therapy to a specific patient with both a high risk of intestinal bleeding and a high risk of thrombosis and thromboembolic complications. The article presents the literature data and own observations on this topic. Modern recommendations for the management of patients are given. A clinical case demonstrating the peculiarities of managing a patient with Crohn's disease and thrombotic complications is presented.

воспалительные заболевания кишечникаязвенный колитболезнь Кронатромбозытромбоэмболиириск кровотечениятерапияinflammatory bowel diseaseulcerative colitisCrohn's diseasethrombosisthromboembolismrisk of bleedingtherapyReferencesAlkim H., Koksal A. R., Boga S. et al. Etiopathogenesis, prevention, and treatment of thromboembolism in inflammatory bowel disease // Clinical and Applied Thrombosis/Hemostasis. 2017. Vol. 23, № 6. P. 501–510. https://doi.org/10.1177/1076029616632906.Alkim H., Koksal A. R., Boga S. et al. Etiopathogenesis, prevention, and treatment of thromboembolism in inflammatory bowel disease. Clinical and Applied Thrombosis/Hemostasis. 2017;23(6):501–510. https://doi.org/10.1177/1076029616632906.Bernstein C. N., Blanchard J. F., Houston D. S., Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study // Thromb Haemost. 2001. Vol. 85. P. 430−4. https://pubmed.ncbi.nlm.nih.gov/11307809.Bernstein C. N., Blanchard J. F., Houston D. S., Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost. 2001;85:430−4. https://pubmed.ncbi.nlm.nih.gov/11307809.Olivera1 P. A., Zuily S., Kotze P. G. et al. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease // Nat Rev Gastroenterol Hepatol. 2021. Vol. 18, № 12. P. 857–873. https://doi.org/10.1038/s41575-021-00492-8.Olivera1 P. A., Zuily S., Kotze P. G. et al. International consensus on the prevention of venous and arterial thrombotic events in patients with infl bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18(12):857–873. https://doi.org/10.1038/s41575-021-00492-8.Kappelman M. D., Horvath-Puho E., Sandler R. S. et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study // Gut. 2011. Vol. 60, № 7. P. 937–43. https://doi.org/10.1136/gut.2010.228585.Kappelman M. D., Horvath-Puho E., Sandler R. S. et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut. 2011;60(7):937–43. https://doi.org/10.1136/gut.2010.228585.Лищинская А. А., Князев О. В., Каграманова А. В. и др. Частота и факторы риска тромбоэмболических осложнений у пациентов с воспалительными заболеваниями кишечника // Терапевтический архив. 2022. Т. 94, № 2. С. 172–179. https://doi.org/10.26442/00403660.2022.02.201367.Lishchinskaya A. A., Knyazev O. V., Kagramanova A. V. et al. Frequency and risk factors for thromboembolic complications in patients with infl bowel diseases. Ter. Arkh. 2022;94(2):172–179. (In Russ.). https://doi.org/10.26442/00403660.2022.02.201367.Isene R., Bernklev T., Høie O. et al. Extraintestinal manifestations in Crohn's disease and ulcerative colitis. P. results from a prospective, population-based European inception cohort // Scand J Gastroenterol. 2015. Vol. 50. P. 300−5. https://doi.org/10.3109/00365521.2014.991752.Isene R., Bernklev T., Høie O. et al. Extraintestinal manifestations in Crohn’s disease and ulcerative colitis: results from a prospective, population-based European inception cohort. Scand J Gastroenterol. 2015;50:300−5. https://doi.org/10.3109/00365521.2014.991752.Vegh Z., Kurti Z., Gonczi L. et al. Association of extraintestinal manifestations and anaemia with disease outcomes in patients with inflammatory bowel disease // Scand J Gastroenterol. 2015. Vol. 50. P. 306−11. https://doi.org/10.3109/00365521.2016.1140807.Vegh Z., Kurti Z., Gonczi L. et al.Association of extraintestinal manifestations and anaemia with disease outcomes in patients with infl mmatory bowel disease. Scand J Gastroenterol. 2015;50:306−11. https://doi.org/10.3109/00365521.2016.1140807.Weng M. T., Park S. H., Matsuoka K. et al. Incidence and risk factor analysis of thromboembolic events in East Asian patients with inflammatory bowel disease, a multinational collaborative study // Inflamm Bowel Dis. 2018. Vol. 24. P. 1791−800. https://doi.org/10.1093/ibd/izy058.Weng M. T., Park S. H., Matsuoka K. et al. Incidence and risk factor analysis of thromboembolic events in EastAsian patients with infl matory bowel disease, a multinational collaborative study. Infl Bowel Dis. 2018;24:1791−800. https://doi.org/10.1093/ibd/izy058.McCurdy J. D., Israel A., Hasan M. et al. Clinical predictive model for post-hospitalisation venous thromboembolism in patients with inflammatory bowel disease // Aliment Pharmacol Ther. 2019. Vol. 49, № 12. P. 1493–1501. https://doi.org/10.1111/apt.15286.McCurdy J. D., Israel A., Hasan M. et al. Clinical predictive model for post-hospitalisation venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2019;49(12):1493–1501. https://doi.org/10.1111/apt.15286.Sarlos P., Szemes K., Hegyi P. et al. Steroid but not biological therapy elevates the risk of venous thromboembolic events in inflammatory bowel disease: A meta-analysis // Journal of Crohn's and Colitis. 2018. Vol. 12, № 4. P. 489–498. https://doi.org/10.1093/ecco-jcc/jjx162.Sarlos P., Szemes K., Hegyi P. et al. Steroid but not biological therapy elevates the risk of venous thromboembolic events in inflammatory bowel disease: A meta-analysis. Journal of Crohn’s and Colitis. 2018;12(4):489–498. https://doi.org/10.1093/ecco-jcc/jjx162.Nguyen G. C., Bernstein C. N., Bitton A. et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology // Gastroenterology. 2014. Vol. 146. P. 835–48. https://doi.org/10.1053/j.gastro.2014.01.042.Nguyen G. C., Bernstein C. N., Bitton A. et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology. 2014;146:835–48. https://doi.org/10.1053/j.gastro.2014.01.042.

The authors declare that there are no conflicts of interest present.